Liposomes as immunological adjuvants: antigen incorporation studies
- PMID: 3604394
- DOI: 10.1016/0264-410x(87)90063-6
Liposomes as immunological adjuvants: antigen incorporation studies
Abstract
Tetanus toxoid was incorporated into liposomes composed of equimolar phospholipid and cholesterol. The toxoid was either passively entrapped into multilamellar vesicles prepared by the dehydration-rehydration procedure (DRV) or covalently coupled by diazotization to the surface of multilamellar vesicles (MLV) prepared by the classical procedure. Up to 82.3% of the antigen used was entrapped in neutral, negatively and positively charged DRV composed of a variety of unsaturated and saturated phospholipids and 63.1% was coupled to MLV composed of egg phosphatidylcholine. After freeze-drying of toxoid-incorporating DRV and MLV and subsequent rehydration, up to 93.5% of the antigen was recovered with liposomes and, in the case of MLV, retained its external localization. Upon freeze-drying in the presence of 0.25 M trehalose, up to 96.1% of the antigen was recovered with the DRV liposomes. In immunization studies using Balb/c mice, DRV composed of equimolar egg phosphatidylcholine and cholesterol were shown to act as immunological adjuvants to the entrapped tetanus toxoid. In addition, there was no difference in immune responses between DRV and MLV of identical composition but bearing the toxoid on their surface. Comparison of immune responses to the toxoid entrapped in DRV made of phospholipids with varying gel to liquid crystalline transition temperature (Tc) revealed a reduction in responses to very low or nil values for DRV made of distearoyl phosphatidylcholine (Tc 54 degrees C).
Similar articles
-
Liposomes as adjuvants with immunopurified tetanus toxoid: influence of liposomal characteristics.Immunology. 1987 Jun;61(2):229-34. Immunology. 1987. PMID: 3596639 Free PMC article.
-
A novel positively-charged lipid 1,2-bis(hexadecylcycloxy)-3-trimethyl aminopropane (BisHOP) enhances the adjuvant effect of liposomes on encapsulated tetanus toxoid.Asian Pac J Allergy Immunol. 1991 Jun;9(1):21-4. Asian Pac J Allergy Immunol. 1991. PMID: 1776976
-
Liposomes as vaccine carriers. Incorporation of soluble and particulate antigens in giant vesicles.J Immunol Methods. 1993 Dec 3;166(2):271-80. doi: 10.1016/0022-1759(93)90368-h. J Immunol Methods. 1993. PMID: 8288880
-
Liposomes as adjuvants with immunopurified tetanus toxoid: the immune response.Immunol Lett. 1987 Apr;14(4):341-8. doi: 10.1016/0165-2478(87)90016-2. Immunol Lett. 1987. PMID: 3583325
-
Liposomes as immunoadjuvants and vaccine carriers: antigen entrapment.Immunomethods. 1994 Jun;4(3):210-6. doi: 10.1006/immu.1994.1022. Immunomethods. 1994. PMID: 7820451 Review.
Cited by
-
Carbon nanotubes as vaccine scaffolds.Adv Drug Deliv Rev. 2013 Dec;65(15):2016-22. doi: 10.1016/j.addr.2013.07.013. Epub 2013 Jul 27. Adv Drug Deliv Rev. 2013. PMID: 23899863 Free PMC article. Review.
-
Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.Vaccine. 2012 Mar 16;30(13):2256-72. doi: 10.1016/j.vaccine.2012.01.070. Epub 2012 Feb 2. Vaccine. 2012. PMID: 22306376 Free PMC article. Review.
-
Primary immune response to liposomal tetanus toxoid in mice: the effect of mediators.Immunology. 1989 Oct;68(2):277-82. Immunology. 1989. PMID: 2509329 Free PMC article.
-
Optimal delivery of vaccines: clinical pharmacokinetic considerations.Clin Pharmacokinet. 1996 Jan;30(1):1-15. doi: 10.2165/00003088-199630010-00001. Clin Pharmacokinet. 1996. PMID: 8846624 Review. No abstract available.
-
Liposome technology for industrial purposes.J Drug Deliv. 2011;2011:591325. doi: 10.1155/2011/591325. Epub 2010 Dec 5. J Drug Deliv. 2011. PMID: 21490754 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources